SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
3D illustration of an RNA molecule
Cardiovascular disease
Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner
The search for a partner for zerlasiran is ongoing, according to Silence. In the meantime, the biotech will focus its resources on divesiran, which it is testing for polycythemia vera and other hematologic indications.
February 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of a hand holding scissors. Copy space for ad. Modern design.
Pipeline
Mission Nixes Preclinical Studies, Falls Back on Clinical Candidates
Mission Therapeutics is down to its clinical assets MTX652 and MTX325, which work by disabling a key enzyme that interferes with the cell’s normal process of removing faulty or dysfunctional mitochondria.
February 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration of two hands shaking while another hand gently grips a wrist
Collaboration
Cassava’s Stock Rises After Licensing Seizure Rights for Embattled Drug Simufilam
The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its Alzheimer’s disease drug simufilam.
February 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Building Patient Trust Amid an Environment of Distrust
While at SCOPE 2025, Sam Srivastava, CEO at WCG Clinical discusses the challenges and responsibilities of the life sciences industry in building public trust amidst growing anger towards healthcare.
February 28, 2025
 · 
1 min read
 · 
Lori Ellis
FDA recently approved BESREMi for the treatment of
Rare diseases
6 Rare Diseases That Have New FDA-Approved Treatments
ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, Niemann-Pick disease type C, metachromatic leukodystrophy and more.
February 28, 2025
 · 
7 min read
 · 
Shawna Williams
mRNA leaves the nucleus, it moves to a ribosome 3d rendering
Opinion
How mRNA Can Help Bridge the Innovation Gap in Rare Disease
As it did during the COVID-19 pandemic, mRNA technology offers an efficient way forward in developing products for diseases that lack approved treatments.
February 28, 2025
 · 
3 min read
 · 
Kyle Holen
Contract Cancellation, Agreement Termination Concept. Couple of Tiny Male Characters Tearing Huge Paper Sheet with Terminated Contract. Businessmen at Workspace. Cartoon People Vector Illustration
Gene therapy
Vertex Severs Liver Gene Therapies Partnership With Verve
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies together.
February 27, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Vector illustration of a hand holding both a businesswoman and a businessman, symbolizing corporate support, care, and equality. Ideal for employee guarantee and security materials
C-suite
GSK CEO Emma Walmsley Gets Pay Bump To Align With Pharma Peers
One of the lowest paid CEOs in pharma—and one of the only woman leading a top-tier giant—is set to receive up to $27.2 million in 2025.
February 27, 2025
 · 
2 min read
 · 
Annalee Armstrong
Illustration of two hands, one thumbs up and one thumbs down
Interviews
The 4 Biggest Job Interview Mistakes Biopharma Professionals Make
As they navigate a competitive job market, biopharma professionals are making four key interview mistakes, according to two talent acquisition experts. They discuss those errors and offer tips for how to get those critical conversations right.
February 27, 2025
 · 
6 min read
 · 
Angela Gabriel
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS